


**Favipiravir (T-705) protects IFNAR<sup>-/-</sup> mice against lethal Zika virus infection in a sex-dependent manner**

Keesha Matz<sup>1§</sup>, Jackson Emanuel<sup>1§#</sup>, Julie Callison<sup>1</sup>, Don Gardner<sup>2</sup>, Rebecca Rosenke<sup>2</sup>, Reinaldo Mercado-Hernandez<sup>1</sup>, Brandi N. Williamson<sup>1</sup>, Heinz Feldmann<sup>1</sup>, and Andrea Marzi<sup>1\*</sup>


<sup>1</sup>Laboratory of Virology, and <sup>2</sup>Rocky Mountain Veterinary Branch, Division of Intramural Research, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Hamilton, MT, USA

§Authors contributed equally.

Supplementary Materials  
Figures S1, S2  
Tables S1-S5



**Figure S1. Gender differences in favipiravir-treated and ZIKV-infected *IFNAR*<sup>-/-</sup> mice.** *IFNAR*<sup>-/-</sup> mice (6-9 weeks old) were infected with ZIKV-French Polynesia treated with 300 mg/kg favipiravir starting 8 hr post-infection and every 24 hrs until day 14. (A) Survival curve for males and females from 8 hr and control groups from Fig. 2C. (B) Survival curve for males and females from favipiravir 300 mg/kg and control groups from Fig. 2A. Statistical significance is indicated as follows: \*\*  $p < 0.01$ .



**Figure S2. Pathological analysis of tissue samples from favipiravir-treated and ZIKV-infected IFNAR<sup>-/-</sup> mice.** IFNAR<sup>-/-</sup> mice were infected with 100 LD<sub>50</sub> (500 PFU) ZIKV-French Polynesia and treated with 300 mg/kg favipiravir 8 hrs post-infection and every 24 hrs until day 14. Tissue samples were collected on day 7 post-infection, fixed with formalin, stained with hematoxylin and eosin (H&E) or probed for ZIKV using *in situ* hybridization (ISH), and imaged at 400x magnification. (A) Vehicle-control treated male mouse testes and epididymis; (B) Vehicle-control and favipiravir-treated female mouse ovary.

Table S1. EC<sub>50</sub> of inhibitors against ZIKV.

Virus	Ribavirin EC <sub>50</sub> (95% CI) [µg / ml]	Favipiravir EC <sub>50</sub> (95% CI) [µg / ml]
ZIKV	4.749 (1.355-22.33)	23.34 (4.246-875.5)
ZIKV-MR766	5.209	34.73
ZIKV-PRVABC59	9.431	10.22
ZIKV-Paraiba	0.4825	7.152
ZIKV-French Polynesia	6.047	6.934

Table S2. SNPs found in the brain of control and favipiravir-treated mice.

Brain							
		Samples successfully sequenced		4/4 animals	3/4 animals	4/4 animals	2/4 animals
				male		female	
				control	favipiravir	control	favipiravir
				day 7	day 7	day 7	day 7
gene	nt location	nt change	amino acid change				
C	376	G -> A	A90T	11.90%			
pr	538	G -> A	A144T			14.60%	
pr	550	C -> T	P148S			11.90%	
pr	722	A -> G	H205R	11.10%			
M	872	C -> T	P255L				10.70%
M	927	C -> T	synonymous			16.9%, 14.20%	
E	1,051	T -> C	synonymous	10.80%			
E	1,093	C -> T	P329S		10.80%		
E	1,242	T -> C	synonymous	38.10%			
E	1,292	G -> A	C395Y			11.10%	
E	1,427	G -> A	G440E	23.80%, 10.30%		69.00%, 45.40%, 30.80%	
E	1,808	T -> C	M567T		15.80%		
E	2,078	A -> T	E657V	22.20%			
E	2,157	G -> A	synonymous	35.70%			
NS1	2,619	A -> C	synonymous			20.80%	
NS1	2,725	C -> A	L873M	16.70%			
NS1	2,786	G -> A	R893K	16.20%			
NS1	2,931	T -> A	H941Q			30.80%	
NS1	2,997	C -> T	synonymous	58.30%	83.30%	37.1%, 36.50%	60.00%
NS1	3,243	C -> T	synonymous				28.60%
NS1	3,459	C -> T	synonymous	39.4%, 19.10%			
NS2A	3,875	C -> T	A1256V				12.20%
NS2A	3,896	C -> T	A1263V	40%, 63.60%, 23.40%	100%, 41.70%	44.60%, 87.30%, 45.90%, 70%	83.30%
NS2A	3,993	C -> T	synonymous		84.60%		
NS2B	4,293	G -> A	synonymous		18.80%		
NS2B	4,323	C -> T	synonymous			20.70%	
NS2B	4,357	T -> G	S1417A	32.10%, 21.30%, 36.80%	40.30%	42.70%, 36.40%, 10.00%	38.20%, 81%
NS3	4,650	A -> G	synonymous				47.10%
NS3	5,058	A -> T	synonymous				25.00%
NS3	5,190	A -> G	synonymous				50.20%
NS3	5,451	T -> C	synonymous			14.00%	
NS3	5,718	C -> T	synonymous			21.20%	
NS3	5,865	C -> T	synonymous	38.90%			
NS3	6,099	C -> T	synonymous	28.60%			
NS4A	6,585	T -> C	synonymous		17.10%		
NS4A	6,678	C -> T	synonymous	24.40%			
NS4A	6,680	T -> C	L2191S			12.90%	
2K	6,885	A -> G	synonymous				40.00%
NS4B	6,948	T -> A	S2280R	12.10%			
NS5	7,900	A -> G	I2598V				45.50%
NS5	8,106	T -> C	synonymous			10.30%	
NS5	8,313	T -> A	synonymous	48.40%			
NS5	8,472	C -> T	synonymous			16.90%	
NS5	8,490	C -> T	synonymous		45.50%		
NS5	8,535	C -> T	synonymous		19.00%		
NS5	8,694	A -> G	I2862M	11.60%			
NS5	9,167	G -> A	G3020E				12.50%
NS5	9,411	C -> T	synonymous			20.90%	
NS5	10,121	T -> A	V3338E		42.90%		
NS5	10,345	T -> C	synonymous				81.80%

Table S3. SNPs found in the spleen of control and favipiravir-treated mice.

Spleen							
		Samples successfully sequenced:		4/4 animals	0/4 animals	2/4 animals	0/4 animals
				male		female	
				control	favipiravir	control	favipiravir
				day 3	n/a	day 3	n/a
gene	nt location	nt change	amino acid change				
M	799	T -> C	S231P	15.50%, 14.90%			
E	1,427	G -> A	G440E	33.70%, 21.60%, 39.40%		14.50%, 24.70%	
NS1	2,593	C -> A	H829N	17.60%			
NS1	2,928	A -> C	K940N			10.90%	
NS1	2,997	C -> T	synonymous	10.10%		16.40%	
NS1	3,150	G -> A	M1014I			16.00%	
NS1	3,283	A -> G	K1059E	16.70%			
NS2A	3,896	C -> T	A1263V	23.90%, 12%, 36.20%		35.20%, 11.20%	
NS2B	4,357	T -> A	S1417T	20%, 10.60%			
NS2B	4,357	T -> G	S1417A	24.70%, 11.80%		16.30%	
NS3	6,373	A -> C	K2089Q	20.40%, 11.50%			
NS5	7,941	C -> T	synonymous	16.70%			
NS5	8,238	T -> C	synonymous	38.2%, 15.40%			
NS5	9,858	C -> T	synonymous	10.00%			

Table S4. SNPs found in the gonads of control and favipiravir-treated mice.

Gonad							
		Samples successfully sequenced:		1/4 animals	0/4 animals	4/4 animals	0/4 animals
				male		female	
				control	favipiravir	control	favipiravir
				day 3 & 7	n/a	day 3	n/a
gene	nt location	nt change	amino acid change				
C	391	A -> G	I95V	12.50%			
pr	722	A -> G	H205R			28.60%	
E	1,140	G -> A	synonymous			10.10%	
E	1,331	A -> G	K408R			10.20%	
E	1,344	C -> T	synonymous	14.80%			
E	1,427	G -> A	G440E			30.70%, 42.90%	
E	2,139	T -> C	synonymous			20.00%	
E	2,170	C -> T	H688Y			18.80%	
NS1	2,758	G -> A	V884M			11.40%	
NS1	2,768	T -> C	V887A			20.50%	
NS1	3,150	G -> A	M1014I			14.20%	
NS2A	3,888	G -> A	synonymous	24.00%			
NS2A	3,896	C -> T	A1263V			18.10%	
NS2A	3,900	C -> T	synonymous			13.00%	
NS2A	4,167	G -> A	synonymous	10.30%			
NS2B	4,357	T -> G	S1417A	64.30%		16%	
NS2B	4,439	C -> T	P1444L	11.40%			
NS3	5,748	G -> A	synonymous	11.10%			
NS3	5,865	C -> T	synonymous	38.90%			
NS3	5,958	C -> T	synonymous	18.20%			
NS3	6,007	A -> G	N1967D	10%			
NS3	6,277	A -> G	T2057A			12.80%	
NS3	6,365	A -> G	Y2086C			31.60%	
NS3	6,373	A -> C	K2089Q	19.40%		33.30%	
NS3	6,447	G -> A	synonymous			10.20%	
NS4A	6,768	G -> A	synonymous			12.90%	
NS4B	7,570	A -> G	T2488A	11.10%			
NS5	7,776	C -> A	truncation			28.60%	
NS5	7,829	C -> T	A2574V			40%	
NS5	7,882	C -> T	truncation			54.50%	
NS5	8,613	A -> G	synonymous			12.90%	
NS5	8,833	C -> T	H2909Y			36.40%	
NS5	9,618	G -> A	synonymous			20.00%	

Table S5. SNPs found in the blood of control and favipiravir-treated mice.

Blood							
		TSamples successfully sequenced:		2/4 animals	1/4 animals	4/4 animals	1/4 animals
				male		female	
				control	favipiravir	control	favipiravir
				day 3	day 3 & 7	day 3	day 3
gene	nt location	nt change	amino acid change				
C	251	T -> C	L48S		11.90%		
C	308	A -> G	N67S	25.00%			
E	1,427	G -> A	G440E	21.60%, 35.90%	25.90%	30.40%	
E	1,446	A -> G	synonymous	10.70%			
E	1,986	T -> C	synonymous	18.20%			
NS1	2,926	A -> G	K940E			16.70%	
NS1	2,997	C -> T	synonymous	25.00%	44%, 33.30%	24.0%, 15.20%	44.00%
NS2A	3,896	C -> T	A1263V	33.30%, 40.70%	59.40%	16%	41.70%
NS2A	4,101	G -> T	synonymous			30.80%	
NS2B	4,357	T -> A	S1417T	18.40%, 12.30%			
NS2B	4,357	T -> G	S1417A	20.40%, 20%	38.10%	33.30%, 20.00%	34.60%
NS3	5,570	C -> T	P1821L	10%			
NS3	6,365	A -> G	Y2086C			28.60%	
NS3	6,373	A -> C	K2089Q			42.90%	
NS5	7,518	T -> C	synonymous		11.80%		
NS5	8,238	T -> C	synonymous	36.40%			
NS5	8,344	A -> G	K2746E	13%			
NS5	9,041	A -> G	K2978R			12.10%	
NS5	9,114	T -> C	synonymous			11.40%	